Clinical trial
A Prospective Randomized Open Label Blinded Endpoint Multicenter Study in Patients With Coronary Artery Disease to Assess the LDL Lowering Effect of Switching to Ezetimibe (+) Simvastatin for Cholesterol Lowering, Compared the Dose of the Statin Used.
NCT00166530 is registered in ClinicalTrials.gov with Organon and Co as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Prospective Randomized Open Label Blinded Endpoint Multicenter Study in Patients With Coronary Artery Disease to Assess the LDL Lowering Effect of Switching to Ezetimibe (+) Simvastatin for Cholesterol Lowering, Compared the Dose of the Statin Used.
- Lead sponsor
- Organon and Co
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- November 30, 2005
- Completion date
- February 28, 2007
- Enrollment
- 367 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.